×
Biogen Inventory 2010-2024 | BIIB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Biogen inventory for the quarter ending September 30, 2024 was
$2.469B
, a
17.21% decline
year-over-year.
Biogen inventory for 2023 was
$2.527B
, a
87.99% increase
from 2022.
Biogen inventory for 2022 was
$1.344B
, a
0.53% decline
from 2021.
Biogen inventory for 2021 was
$1.352B
, a
26.47% increase
from 2020.
View More
Biogen Inventory 2010-2024 | BIIB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Biogen inventory for 2023 was
$2.527B
, a
87.99% increase
from 2022.
Biogen inventory for 2022 was
$1.344B
, a
0.53% decline
from 2021.
Biogen inventory for 2021 was
$1.352B
, a
26.47% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$174.8B
Vertex Pharmaceuticals (VRTX)
$133.1B
Gilead Sciences (GILD)
$120.2B
Bristol Myers Squibb (BMY)
$109.8B
Regeneron Pharmaceuticals (REGN)
$91B
CSL (CSLLY)
$90.5B
GSK (GSK)
$75.2B
Alnylam Pharmaceuticals (ALNY)
$35.8B
Argenex SE (ARGX)
$35.6B
BioNTech SE (BNTX)
$26.3B
Illumina (ILMN)
$24B
BeiGene (BGNE)
$20B
Moderna (MRNA)
$18B
Incyte (INCY)
$16.1B
Genmab (GMAB)
$15.3B
Vaxcyte (PCVX)
$13.3B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$12.8B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.6B
Exelixis (EXEL)
$10.4B
Revolution Medicines (RVMD)
$10.2B
QIAGEN (QGEN)
$10B
Intra-Cellular Therapies (ITCI)
$9.7B
Exact Sciences (EXAS)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.8B
Repligen (RGEN)
$7.9B
Halozyme Therapeutics (HALO)
$7.8B
Viking Therapeutics (VKTX)
$7.6B